Intellia Therapeutics, Inc.
NTLA
$9.52
-$2.80-22.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -14.33% | 29.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -14.33% | 29.15% | |||
| Cost of Revenue | -25.73% | -7.23% | |||
| Gross Profit | 27.79% | 11.73% | |||
| SG&A Expenses | 50.68% | -10.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.60% | -7.96% | |||
| Operating Income | 8.95% | 11.46% | |||
| Income Before Tax | 11.44% | 11.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.44% | 11.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.44% | 11.30% | |||
| EBIT | 8.95% | 11.46% | |||
| EBITDA | 9.12% | 11.63% | |||
| EPS Basic | 11.63% | 12.71% | |||
| Normalized Basic EPS | 8.78% | 12.23% | |||
| EPS Diluted | 11.63% | 12.71% | |||
| Normalized Diluted EPS | 8.78% | 12.23% | |||
| Average Basic Shares Outstanding | 0.22% | 1.62% | |||
| Average Diluted Shares Outstanding | 0.22% | 1.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||